Skip to content

Effect of hydroxychloroquine on blood sugars among patients diagnosed with rheumatoid arthritis and diabetes

Effect of hydroxychloroquine on glycaemic status in patients with rheumatoid arthritis and type II diabetes mellitus

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/12/016680
Enrollment
196
Registered
2018-12-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M959- Acquired deformity of musculoskeletal system, unspecified Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: hydroxychloroquine based regimen: Combination of drugs containing Hydroxychloroquine Tablet Hydroxychloroquine 200mg once daily if needed escalated to 400mg once daily Control Interven

Sponsors

Dr Asha B
Lead Sponsor
Sri Devaraj Urs Academy of Higher Education and Research
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 2) Rheumatoid arthritis diagnosed based on American College of Rheumatology criteria (both seropositive and seronegative are included) 3) Type II diabetes with any one of the oral drug for diabetes 4) Fasting blood sugar 126-250 mg/dl and Post prandial blood sugar 200- 350mg/dl 5) HbA1c levels in the range of 6.6- 12%

Exclusion criteria

Exclusion criteria: 1) History of taking chloroquine and its derivatives, insulin preparations and corticosteroids or other hormone derivatives in the past 3 months 2) History of allergy to hydroxychloroquine

Design outcomes

Primary

MeasureTime frame
1) To determine the effect of hydroxychloroquine on Fasting Blood Sugar (FBS), Post Prandial Blood Sugar (PPBS) and Glycated Hemoglobin (HbA1C) in patients with rheumatoid arthritis and type II diabetes mellitusTimepoint: 3 and 6 months

Secondary

MeasureTime frame
2) To assess the adverse effects in hydroxychloroquine based and non hydroxychloroquine based regimen in the above mentioned patients.Timepoint: 3 and 6 months

Countries

India

Contacts

Public ContactDr Asha B

Sri Devaraj Urs Medical College

dr.ashareddy@gmail.com09972100450

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026